IMMX | tickerfilter.com

Fundamental analysis

28%

Profitability 0%

Dept financing 32%

Liquidity 50%

Performance 50%

Company vs Stock growth

N/A

1.720 1.820

0.100 5.81%

+ Add row to compare

Performance

5 Days

-4.43%

1 Month

-3.21%

3 Months

-32.89%

6 Months

-1.31%

1 Year

-47.20%

2 Year

-12.21%

Key data

Stock price

$1.51

P/E Ratio

0.00

DAY RANGE

$1.45 - $1.62

EPS

-$0.76

52 WEEK RANGE

$1.26 - $2.93

52 WEEK CHANGE

-$46.83

MARKET CAP

60.517 M

YIELD

N/A

SHARES OUTSTANDING

27.450 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.77

PUBLIC FLOAT

AVERAGE 10 VOLUME

$49,108

AVERAGE 30 VOLUME

$44,443

Company detail

CEO: Ilya Rachman
Region: US
Website: immixbio.com
Employees: 9
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Immix Biopharma, Inc. engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination clinical trial in solid tumors of IMx-110 and anti-PD-1 Tislelizumab.

IMMX - Immix Biopharma, Inc.